CG Oncology Q2 2026: $1.0B Cash, $79.1M Net Loss, and Key Pipeline Milestones on the Horizon
CGON has more than doubled off its 52-week low of $23.65.
Summary
CG Oncology's Q2 2026 results show a $79.1 million net loss and $1.0 billion in cash, with upcoming pivotal trial data and a BLA submission serving as key value drivers.
Key Events · Earnings and Guidance · CGON
-
Q2 2026 Financial Results
Driven by higher R&D ($54.7M) and G&A ($29.0M) expenses, the net loss widened to $79.1 million ($0.90/share) from $60.2 million in Q1 2026. A cash position of $1.0 billion is expected to fund operations through 2029.
-
PIVOT-006 Phase 3 Topline Data Imminent
With the vast majority of target events now accrued, topline results from the pivotal trial in intermediate-risk NMIBC are anticipated in the near-term — a major catalyst for the stock.
-
BLA Submission on Track for Q4 2026
Completion of the Biologics License Application for cretostimogene in high-risk BCG-unresponsive NMIBC is expected in the fourth quarter of 2026, marking a key regulatory milestone.
-
Lancet Oncology Publication Validates BOND-003
Strengthening the clinical evidence for cretostimogene, results from the BOND-003 Cohort C study were published in The Lancet Oncology.
Analysis · CGON · Life Sciences
A wider net loss of $79.1 million in Q2 2026, up from $60.2 million in Q1, reflects rising clinical trial and compensation costs. Even so, the company's $1.0 billion cash position is expected to fund operations through 2029. Near-term catalysts include topline data from the pivotal PIVOT-006 Phase 3 trial in intermediate-risk NMIBC and a BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC, targeted for Q4 2026. Adding further validation, results from the BOND-003 Cohort C study were published in The Lancet Oncology. A favorable legal ruling in the ANI dispute also removes a potential overhang. These updates arrive just hours after the company expanded its ATM program by $500 million to $1.05 billion, signaling continued capital access but also the prospect of future dilution.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGON was trading at $71.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $23.65 to $77.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.